3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
50
Leukemia
15
Gastrointestinal Stromal Tumors
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Myeloid, Chronic-Phase
8
Neoplasms
5
Philadelphia Chromosome
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Blast Crisis
4
Hematologic Diseases
3
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Recurrence
1
Piebaldism
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Melanoma
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Accelerated Phase
1
Hypereosinophilic Syndrome
1
Disease Progression
1
Interventions
pembrolizumab
2
Pemetrexed
2
nilotinib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
Zoledronic Acid
1
Trastuzumab
1
MRX-2843
1
Denosumab
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplastic Processes
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA